Maravai LifeSciences Sees Unusually Large Options Volume (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) saw unusually large options trading on Wednesday. Traders bought 1,002 put options on the company. This is an increase of 1,791% compared to the typical daily volume of 53 put options.

Insider Buying and Selling

In related news, General Counsel Kurt Oreshack sold 25,000 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $5.03, for a total transaction of $125,750.00. Following the completion of the transaction, the general counsel now directly owns 167,618 shares of the company’s stock, valued at approximately $843,118.54. This trade represents a 12.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.63% of the stock is owned by insiders.

Institutional Investors Weigh In On Maravai LifeSciences

A number of institutional investors have recently added to or reduced their stakes in MRVI. Delta Investment Management LLC lifted its position in shares of Maravai LifeSciences by 285.4% during the fourth quarter. Delta Investment Management LLC now owns 332,993 shares of the company’s stock valued at $1,815,000 after buying an additional 246,592 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Maravai LifeSciences by 22.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 251,214 shares of the company’s stock worth $1,369,000 after acquiring an additional 45,454 shares in the last quarter. Systematic Financial Management LP increased its stake in Maravai LifeSciences by 2.3% during the 4th quarter. Systematic Financial Management LP now owns 1,649,544 shares of the company’s stock valued at $8,990,000 after purchasing an additional 37,383 shares in the last quarter. Sherbrooke Park Advisers LLC acquired a new position in shares of Maravai LifeSciences in the fourth quarter valued at about $78,000. Finally, ProShare Advisors LLC grew its position in Maravai LifeSciences by 89.8% during the 4th quarter. ProShare Advisors LLC now owns 55,488 shares of the company’s stock worth $302,000 after purchasing an additional 26,251 shares during the period. Institutional investors own 50.25% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on MRVI shares. Wolfe Research assumed coverage on Maravai LifeSciences in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. Robert W. Baird lowered their target price on shares of Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating for the company in a report on Friday, November 8th. Guggenheim started coverage on shares of Maravai LifeSciences in a report on Thursday, December 19th. They set a “neutral” rating on the stock. William Blair reaffirmed a “market perform” rating on shares of Maravai LifeSciences in a research note on Friday, November 8th. Finally, Royal Bank of Canada decreased their price target on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. One research analyst has rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Maravai LifeSciences has a consensus rating of “Hold” and a consensus price target of $10.28.

Maravai LifeSciences Stock Performance

Shares of NASDAQ:MRVI opened at $3.95 on Friday. The company has a quick ratio of 9.94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89. The company has a market capitalization of $997.49 million, a price-to-earnings ratio of -2.41 and a beta of -0.08. The firm has a 50 day moving average of $5.09 and a 200 day moving average of $6.71. Maravai LifeSciences has a 52 week low of $3.94 and a 52 week high of $11.56.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.